On November 1, 2023, VYNE Therapeutics Inc. closed the transaction.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.67 USD | +0.75% | +1.91% | +14.59% |
May. 09 | Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q1 Revenue $98,000 | MT |
May. 09 | VYNE Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.59% | 37.64M | |
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
-2.71% | 159B |
- Stock Market
- Equities
- VYNE Stock
- News VYNE Therapeutics Inc.
- VYNE Therapeutics Inc. announced that it has received $88.151509 million in funding from Acorn Bioventures, Parkman Healthcare Partners LLC, Soleus Capital, Surveyor Capital Management, Palo Alto Investors LP and other investors